Castle Biosciences Announces Availability of DecisionDx-EC Esophageal Cancer Tes

Castle Biosciences, a leading prognostic and molecular diagnostic company in Texas, has announced the release of a multi-biomarker test,Â DecisionDx-ECÂ that helps in predicting the prognosis and resistance to chemo-radiation therapy inÂ esophageal cancerÂ patients before surgery.
http://bionews-tx.com/news/2013/06/20/castle-biosciences-announces-availability-of-decisiondx-ec-esophageal-cancer-test/

AUDIENCES

Caregivers
Friends and Family
General Public
Medical Profession
Patients
Survivors

SUBJECTS

Post Surgical

Disclaimer: This information is for educational purposes only, It is not to diagnose or treat your disease. If you do use the information contained on this web site without the approval of a health professional, you are prescribing for yourself, which is your constitutional right, but the author(s) and webmaster assume no responsibility

© 2024 Esophageal Cancer Education Foundation- by domino